MID-VOLUME · SEX-BALANCED

baricitinib Side Effects

baricitinib (also sold as Olumiant) sits MID-VOLUME #328 of 524 by FAERS report count. Lead signal: SEX-BALANCED - 67% of sex-coded reports are female (5,641 F / 2,741 M). Demographics and serious-outcome tables follow.

Data updated 2026-05-15

9,259
FAERS reports

FDA Adverse Event Reporting System extract for baricitinib. Stamp set WATCHLIST · DEATH-HEAVY · HOSP-HEAVY. How figures are compiled.

baricitinib reporting skew - 67% of sex-coded reports are female (5,641 F / 2,741 M). Volume band MID-VOLUME #328 of 524 by FAERS report count; caseload WATCHLIST.

Mid-book FAERS page for baricitinib (Olumiant) (9,259 reports). Signature SEX-BALANCED. Dominant age band on file: 45-64. Educational reference only.

Counts from the openFDA FAERS extract (2012–2025). Stamps WATCHLIST · DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED.

COVID-19 leads 439 of 9,259 reports

COVID-19
439
RHEUMATOID ARTHRITIS
352
PULMONARY EMBOLISM
294
PNEUMONIA
264
HEADACHE
253
HERPES ZOSTER
237
DEATH
235
NAUSEA
226
DEEP VEIN THROMBOSIS
213
FATIGUE
183
ARTHRALGIA
179
WEIGHT INCREASED
179
THERAPY INTERRUPTED
178
DYSPNOEA
174
URINARY TRACT INFECTION
174
PAIN
173
DIARRHOEA
165
RASH
156

Who reports · age peak 45-64 (SEX-BALANCED)

Sex coding · SEX-BALANCED

Female 5,641 (67%)
Male 2,741 (33%)
Unknown 1

Age peak 45-64 (2,625 reports)

0-17 184 (3%)
18-44 1,111 (17%)
45-64 2,625 (40%)
65-74 1,623 (25%)
75+ 1,022 (16%)

FAERS filings rising toward 2025

12
13
14
15
16
17
18
19
20
21
22
23
24
25

Reactions in Death Reports

Death-mentioned subset is HEAVY here (866 reports, 9.4%). Top co-reported reactions in that subset - voluntary, not causal.

Reaction Reports
DEATH 229
COVID-19 80
RESPIRATORY FAILURE 48
CARDIAC ARREST 45
COVID-19 PNEUMONIA 41
SEPSIS 41
PULMONARY EMBOLISM 39
MULTIPLE ORGAN DYSFUNCTION SYNDROME 34
PNEUMONIA 33
SEPTIC SHOCK 28
ACUTE KIDNEY INJURY 27
ACUTE RESPIRATORY DISTRESS SYNDROME 25
CARDIO-RESPIRATORY ARREST 24
CARDIAC FAILURE 22
ACUTE RESPIRATORY FAILURE 21
ISCHAEMIC STROKE 21
BRONCHOPULMONARY ASPERGILLOSIS 20
DYSPNOEA 20

Reactions in Hospitalization Reports

Hospitalization is HEAVY (3,011, 32.5% of the book). Top reactions in those rows:

Reaction Reports
COVID-19 227
PNEUMONIA 185
RHEUMATOID ARTHRITIS 181
PULMONARY EMBOLISM 154
DEEP VEIN THROMBOSIS 109
DYSPNOEA 99
HERPES ZOSTER 88
PYREXIA 83
ARTHRALGIA 77
URINARY TRACT INFECTION 75
ARTHRITIS 73
ACUTE KIDNEY INJURY 72
FALL 71
RESPIRATORY FAILURE 70
VOMITING 69
COVID-19 PNEUMONIA 65
SEPSIS 63
ANAEMIA 62
How to read baricitinib FAERS figures (WATCHLIST · DEATH-HEAVY · HOSP-HEAVY)

FAERS holds 9,259 voluntary reports linked to baricitinib (Olumiant), 2012-2025. Death is listed on 866 (9.4%). Hospitalization appears on 3,011 (32.5%). Top co-reported indication: Rheumatoid Arthritis.

Mid-volume extract - treat DEATH-HEAVY · HOSP-HEAVY as signal-detection rates next to 67% of sex-coded reports are female (5,641 F / 2,741 M).

Read with baricitinib

Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-HEAVY stamps.